Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

被引：0
|
作者：
Dobric, N. [1 ]
Dandachi, N. [1 ]
Klocker, E. V. [1 ]
Suppan, C. [1 ]
Graf, R. [2 ]
Hasenleithner, S. [2 ]
Jost, P. J. [1 ]
Heitzer, E. [2 ]
Balic, M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Human Genet, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
491P
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [41] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    CANCER RESEARCH, 2016, 76
  • [42] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [43] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [44] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [45] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [46] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
    Dalal, Anand A.
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (09) : 1356 - 1367
  • [47] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer
    Anand A. Dalal
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Rebecca Burne
    Annie Guérin
    Polly Niravath
    Tania Small
    Advances in Therapy, 2018, 35 : 1356 - 1367
  • [48] Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-advanced breast cancer
    Tremblay, Gabriel
    Chandiwana, David
    Dolph, Mike
    Hearnden, Jaclyn
    Forsythe, Anna
    Monaco, Mauricio
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1319 - 1327
  • [49] HER2-low versus HER2-0 in Invasive Lobular Breast Carcinoma
    Fontes-Sousa, M.
    de Sousa, L.
    Ribeiro, L.
    Torres, S. Pinto
    Costa, D. Alpuim
    Pinto, C. Gama
    Mestre, L.
    Borralho, P.
    Raimundo, A.
    Negreiros, I.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S86 - S87
  • [50] ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
    Venetis, Konstantinos
    Pepe, Francesco
    Pescia, Carlo
    Cursano, Giulia
    Criscitiello, Carmen
    Frascarelli, Chiara
    Mane, Eltjona
    Russo, Gianluca
    Salimbeni, Beatrice Taurelli
    Troncone, Giancarlo
    Rocco, Elena Guerini
    Curigliano, Giuseppe
    Fusco, Nicola
    Malapelle, Umberto
    CANCER TREATMENT REVIEWS, 2023, 121
12345